Santa Ana Bio, Inc.

Based in California, US, and founded by Peter Emtage (CEO) in 2022, Santa Ana Bio, Inc. operates as a biotechnology company that develops pharmaceutical medicines for patients with autoimmune and inflammatory diseases. In June 2024, Santa Ana Bio, Inc. raised USD 125 million in series B funding led by investor GV, with participation from other investors RTW Investments, Access Industries, Andreessen Horowitz, Versant Ventures, and Life Sci­ence Inno­va­tions.

The precision immunology company focuses on developing targeted therapies by leveraging multi-omics platforms and advanced antibody engineering. Santa Ana has established a pipeline of novel therapeutics, including monoclonal antibodies, bi-specific antibodies, and antibody-drug conjugates (ADCs). Notable programs include SAB01, a bi-specific antibody that conditionally blocks the c-Kit receptor to treat allergic diseases with reduced toxicity; SAB03, which targets PD-1 to treat rheumatoid arthritis by eliminating pathogenic T cells; and SAB05, an ADC program that harnesses glucocorticoid efficacy while minimizing side effects. Additionally, Santa Ana Bio's proprietary SIERRA platform integrates multi-modal patient data to gain deep insights into the cellular and immune pathways underlying immune-mediated diseases.

This platform enables the rapid advancement of therapeutic programs from concept to clinical trials, ensuring precise targeting of disease pathways and minimizing broad immune suppression. The company plans to utilize the June 2024 funding to accelerate its research and development initiatives.